Table 1 Patient baseline characteristics
Spacer (n = 40) | ||
|---|---|---|
n | % | |
Age, years | ||
Median (range) | 70 (55–79) | |
BMI, kg/m2 | ||
Median (range) | 23.8 (19.7–31.2) | |
Performance status | ||
0 | 16 | 40 |
1 | 24 | 60 |
Pre-treatment PSA, ng/mL | ||
Median (range) | 8.6 (2.3–195) | |
≤ 10 | 25 | 62.5 |
10–20 | 11 | 27.5 |
20> | 4 | 10 |
Gleason score | ||
6 | 4 | 10 |
7 | 24 | 60 |
8 | 6 | 15 |
9 | 6 | 15 |
Clinical T stage | ||
T1c | 8 | 20 |
T2a | 19 | 47.5 |
T2b | 1 | 2.5 |
T2c | 9 | 22.5 |
T3a | 2 | 5 |
T3b | 1 | 2.5 |
Risk group | ||
Low | 3 | 7.5 |
Intermediate | 25 | 62.5 |
High | 6 | 15 |
Very high | 6 | 15 |
Androgen deprivation therapy | ||
Yes | 23 | 57.5 |
No | 17 | 42.5 |
PSA at RT initiation, ng/mL | ||
Median (range) | 3.5 (0.02–16.3) | |
Anti-coagulation or platelet treatment | ||
Yes | 6 | 15 |
No | 34 | 85 |
History of abdominal surgery | ||
Yes | 9 | 22.5 |
No | 31 | 77.5 |
Diabetes | ||
Yes | 5 | 12.5 |
No | 35 | 87.5 |
Smoking | ||
Never | 12 | 30 |
Past | 26 | 65 |
Current | 2 | 5 |